CDK4 and breast carcinoma: This has led to the clinical development of endocrine-based combination therapies such as the SERD, fulvestrant, together with the cyclin dependent kinase 4/6 (CDK4/6) inhibitor palbociclib/PD-0332991, which collectively prolong survival of patients with advanced ER+ breast cancer [4].